Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

NCT01391611 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped Lack of efficacy - Futility endpoint reached

Conditions

Gastrointestinal Stromal Tumor (GIST)

Interventions

DRUG: Pazopanib

Sponsor

Kristen Ganjoo

Collaborators

[object Object]